AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation.
about
Somatic Activating PIK3CA Mutations Cause Venous MalformationTargeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapyActivation of PKCα and PI3K Kinases in Hypertrophic and Nodular Port Wine Stain LesionsMolecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.Pediatric lymphatic malformations: evolving understanding and therapeutic options.Rapamycin up-regulates triglycerides in hepatocytes by down-regulating Prox1Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital HemangiomamiR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cellsRapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract.Vegfc acts through ERK to induce sprouting and differentiation of trunk lymphatic progenitors.Utilizing lymphatic cell markers to visualize human lymphatic abnormalities.PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies.The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.Cancer-Associated PIK3CA Mutations in Overgrowth Disorders
P2860
Q28270654-EBCF2000-8CE7-46B1-AA56-9DD92D66719CQ29248893-6C94850C-F8F6-4AE9-A9D0-3C7C4E8B24ECQ30490586-AE475176-1A7B-4324-9B71-68D01E3D8DD9Q35542297-5A7244F6-0F32-4EE9-AB9B-4EF28B5D2886Q35905671-FF76B583-FDD1-48AF-A2A2-DEC92C335BD6Q36626489-45F36481-43F8-4C9B-BDB7-16075FCC9A6EQ36802954-8D597069-4AD0-433D-9295-975482E728C5Q38554814-6B5E1103-D15A-45B2-8D2E-358A6BA4923CQ41970819-F2939152-F9FC-4AC9-80F8-8A0229C47A81Q42377401-A939A786-1275-43F4-A3C8-32DD75D32C54Q48133682-FB73CF9E-E2BA-43C8-8CD2-FC75D8C61027Q48204602-EBBE723A-2462-42F8-8962-ADB8C39BEBF1Q49711122-446CD965-49DA-4F82-878C-FFBF19001BE8Q55435506-C4384EEC-761A-44DC-AFC2-F47CFED87B94Q58035745-A257AEDE-B909-40E3-8600-E75FBAE8805B
P2860
AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
AKT hyper-phosphorylation asso ...... t with lymphatic malformation.
@ast
AKT hyper-phosphorylation asso ...... t with lymphatic malformation.
@en
type
label
AKT hyper-phosphorylation asso ...... t with lymphatic malformation.
@ast
AKT hyper-phosphorylation asso ...... t with lymphatic malformation.
@en
prefLabel
AKT hyper-phosphorylation asso ...... t with lymphatic malformation.
@ast
AKT hyper-phosphorylation asso ...... t with lymphatic malformation.
@en
P2093
P2860
P921
P1433
P1476
AKT hyper-phosphorylation asso ...... nt with lymphatic malformation
@en
P2093
Arin K Greene
Matthew L Warman
Michael Klagsbrun
Silvia Coma
Valerie L Luks
P2860
P2888
P304
P356
10.1007/S10456-014-9453-2
P577
2014-11-26T00:00:00Z